Get the Stockscreener App
9.37
6.02%
-0.60
After Hours:
9.30
-0.07
-0.75%
Personalis Inc stock is traded at $9.37, with a volume of 1.01M.
It is down -6.02% in the last 24 hours and up +17.57% over the past month.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
See More
Previous Close:
$9.97
Open:
$9.75
24h Volume:
1.01M
Relative Volume:
0.68
Market Cap:
$832.10M
Revenue:
$73.48M
Net Income/Loss:
$-108.30M
P/E Ratio:
-4.1644
EPS:
-2.25
Net Cash Flow:
$-67.17M
1W Performance:
-7.87%
1M Performance:
+17.57%
6M Performance:
+67.62%
1Y Performance:
+74.81%
1-Day Range:
$9.21
$9.935
1-Week Range:
$9.21
$10.69
52-Week Range:
$2.8262
$11.50
Personalis Inc Stock (PSNL) Company Profile
Name
Personalis Inc
Sector
Industry
Phone
650-752-1300
Address
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
9.37 | 885.38M | 73.48M | -108.30M | -67.17M | -2.25 |
|
TMO
Thermo Fisher Scientific Inc
|
578.61 | 222.48B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
218.89 | 155.25B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
670.46 | 54.04B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
230.15 | 40.13B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
133.85 | 37.78B | 6.95B | 1.30B | 1.15B | 4.5696 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-15-25 | Initiated | Guggenheim | Buy |
| Mar-17-25 | Initiated | Craig Hallum | Buy |
| Feb-06-23 | Upgrade | Needham | Hold → Buy |
| Jan-07-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-03-21 | Downgrade | Needham | Buy → Hold |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-20-21 | Reiterated | Needham | Buy |
| May-06-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-21 | Initiated | Truist | Buy |
| Jan-04-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-12-20 | Reiterated | Needham | Buy |
| Nov-06-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-19-20 | Initiated | Citigroup | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Aug-18-20 | Initiated | Needham | Buy |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-15-19 | Initiated | BofA/Merrill | Neutral |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Morgan Stanley | Overweight |
| Jul-15-19 | Initiated | Oppenheimer | Outperform |
View All
Personalis Inc Stock (PSNL) Latest News
Personalis, Inc. (PSNL) Stock Analysis: A 11.76% Potential Upside Amidst Revenue Challenges - DirectorsTalk Interviews
Wall Street Zen Upgrades Personalis (NASDAQ:PSNL) to Hold - Defense World
Is Personalis Inc.’s growth already priced inJuly 2025 Recap & Consistent Return Strategy Ideas - mfd.ru
Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference - BioSpace
Insider Selling: Personalis (NASDAQ:PSNL) CFO Sells $13,811.50 in Stock - Defense World
What 9 Analyst Ratings Have To Say About Personalis - Benzinga
Guggenheim Raises Price Target for Personalis (PSNL) to $13.00 | - GuruFocus
Gainers Report: Is Personalis Incs growth already priced inShare Buyback & Entry Point Strategy Guides - baoquankhu1.vn
Personalis (NASDAQ:PSNL) Sets New 12-Month High – Still a Buy? - Defense World
Hedge Fund Bets: Should you avoid Personalis Inc stock right nowEarnings Risk Summary & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Personalis, Inc. $PSNL Shares Purchased by AIGH Capital Management LLC - MarketBeat
Personalis (NASDAQ:PSNL) CFO Sells $13,811.50 in Stock - MarketBeat
Personalis CFO Tachibana sells $13,811 in shares By Investing.com - Investing.com Australia
Personalis CFO Tachibana sells $13,811 in shares - Investing.com
Personalis (NASDAQ:PSNL) Reaches New 12-Month HighWhat's Next? - MarketBeat
Personalis Sees Revised Reimbursement Rates for Cancer Tests - MSN
Personalis (NASDAQ:PSNL) Trading 14.8% HigherStill a Buy? - MarketBeat
Market Rankings: How does PLRX perform in inflationary periodsWeekly Stock Recap & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
How A New Price Target Is Shaping The Evolving Story For Personalis (PSNL) - Yahoo Finance
Winners Losers: Is Personalis Incs growth already priced inDollar Strength & Risk Controlled Daily Plans - baoquankhu1.vn
Personalis, Inc. (NASDAQ:PSNL) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Trading Action: Can Personalis Inc grow without external fundingJuly 2025 Volume & Weekly High Return Stock Forecasts - baoquankhu1.vn
Personalis, Inc. (NASDAQ:PSNL) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable - simplywall.st
Personalis (NASDAQ:PSNL) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Personalis, Inc. (PSNL) Stock Analysis: A Promising 14.46% Upside Potential Amid Strategic Collaboration - DirectorsTalk Interviews
Aug Closing: Is Personalis Inc a defensive stockMarket Volume Report & Technical Pattern Recognition Alerts - baoquankhu1.vn
Aug Technicals: Is Personalis Inc showing insider buyingRate Cut & Reliable Momentum Entry Alerts - baoquankhu1.vn
cathie wood’s ARK stock trades highlight intellia, personalis buys By Investing.com - Investing.com Nigeria
cathie wood’s ARK stock trades highlight intellia, personalis buys - Investing.com
Personalis Stock Pre-Market (-4.0%): Downgrade Cites Competitive Headwinds - Trefis
Stop Loss: Can Personalis Inc stock double in the next yearTreasury Yields & Verified Swing Trading Watchlists - baoquankhu1.vn
Can Personalis Inc stock double in the next yearTrade Analysis Summary & Scalable Portfolio Growth Methods - baoquankhu1.vn
Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™ - FinancialContent
Risk Hedge: Is Personalis Inc benefiting from interest rate changesWeekly Market Outlook & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Personalis, Inc. Announces Early Access Launch of Real-Time Variant Tracker - marketscreener.com
Personalis Reports Q3 2025 Financial Results - MSN
Will Personalis Inc. (04X) stock split increase liquidityWeekly Loss Report & Free Accurate Trade Setup Notifications - ulpravda.ru
Personalis (NASDAQ:PSNL) Given “Buy” Rating at BTIG Research - Defense World
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates - sharewise.com
BTIG Reiterates Buy Rating for Personalis (PSNL) with $12 Target - GuruFocus
BTIG Research Reaffirms Buy Rating for Personalis (NASDAQ:PSNL) - MarketBeat
Is Personalis Inc. stock attractive for long term wealth building2025 Historical Comparison & Expert Curated Trade Setups - Улправда
Why Personalis Inc. stock remains a top recommendationJuly 2025 Market Mood & Risk Controlled Stock Alerts - Улправда
Is Personalis Inc. stock attractive for hedge fundsEarnings Recap Summary & Consistent Return Strategy Ideas - ulpravda.ru
Personalis (PSNL) Achieves Remarkable Growth in Clinical Volumes - GuruFocus
Can Personalis Inc. stock outperform in 2025 bull marketGap Down & Real-Time Buy Zone Alerts - ulpravda.ru
Is Personalis Inc. stock a buy for dividend growth2025 Macro Impact & Real-Time Chart Breakout Alerts - Улправда
Will Personalis Inc. stock remain a Wall Street favoriteQuarterly Portfolio Report & Risk Adjusted Swing Trade Ideas - Улправда
The $537B Precision Pivot: Why Molecular Monitoring is the New Oncology Standard - The Globe and Mail
Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights - BioSpace
PSNL Achieves Key Medicare Coverage Milestone for Breast Cancer - GuruFocus
Personalis Inc Stock (PSNL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.19%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):